Health Technology · Pharmaceuticals: Major · NSE: INDGN · data 2026-10-09
Indegene Limited
Health check: Strong (7/10 on quality, valuation vs sector, growth and momentum).
Open full analysis — chart, results, balance sheet, red flags →Key figures
Price
₹580.1
Market cap
₹14,112 cr
P/E
35
P/B
—
ROE
13.9%
ROCE
15.9%
Debt / equity
0.05
Dividend yield
0.38%
1-year return
4.5%
52-week high
₹627
52-week low
₹414
Operating margin
12.8%
Growth
| Revenue (last 12 months) | ₹3,813 cr |
| Net profit (last 12 months) | ₹401 cr |
| Sales growth, 3 years (yearly) | 15.0% |
| Profit growth, 3 years (yearly) | 14.7% |
Chart patterns
- Double top — forming (key level ₹559)
- Ascending triangle — forming (key level ₹627)
Similar companies
Alembic Pharmaceuticals Limited (APLLTD) · NATCO Pharma Limited (NATCOPHARM) · Jubilant Pharmova Limited (JUBLPHARMA) · AstraZeneca Pharma India Limited (ASTRAZEN) · Marksans Pharma Limited (MARKSANS)
The full analysis has the price chart, every quarterly result with YoY/QoQ growth, the balance sheet and cash flow with an accounting red-flag check, shareholding quarter by quarter with big investors, news, filings and bulk/block deals.
Open INDGN in NSE Scanner →